SCHEMBL7336808

SCHEMBL7336808

CNC(=O)Nc1cccc2ccc(C(=N)N)cc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.71
F2 P00734 3/20 0.54
PLG P00747 3/20 0.54
KLK1 P06870 3/20 0.54
PRSS1 P07477 3/20 0.54
PLAT P00750 2/20 0.54
F10 P00742 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
RECQL P46063 1/20 0.47
TRPV1 Q8NER1 4/20 0.47
KDM4E B2RXH2 3/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
KLKB1 P03952 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28742391 0.86 PLAU (0.75) PLAUF2PLGKLK1PRSS1
SCHEMBL7335597 0.85 PLAU (0.74) PLAUF2PLGKLK1PRSS1
SCHEMBL7335327 0.84 PLAU (0.72) PLAUF2PLGKLK1PRSS1
SCHEMBL7341340 0.82 PLAU (0.70) PLAUF2PLGKLK1PRSS1
SCHEMBL7344902 0.81 PLAU (0.67) PLAUF2PLGKLK1PRSS1
SCHEMBL7334054 0.79 PLAU (0.73) PLAUF2PLGKLK1PRSS1
SCHEMBL27541098 0.79 PLAU (0.73) PLAUF2PLGKLK1PRSS1
Bromide SCHEMBL10348696 0.78 TRPV1 (0.68) TRPV1KDM4ERAB9AKMT2AMEN1
Hydrochloric Acid SCHEMBL10348748 0.78 TRPV1 (0.68) TRPV1KDM4ERAB9AKMT2AMEN1
Iodide SCHEMBL10348458 0.78 TRPV1 (0.68) TRPV1KDM4ERAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
CN-1265645-A Urokinase inhibitors ABBOTT LAB (US) 2000-09-06 CN claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885PLG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.